Pramodini Medicare IPO

Incorporated in 2000, Pramodini Medicare Limited is a diagnostic service provider in India offering technology-enabled diagnostic services across radiology, clinical laboratory, and nuclear medicine segments. The company provides services to public hospitals, private hospitals, public sector undertakings (PSUs), medical colleges, and private diagnostic centres across tier I, II, and III cities. Its service portfolio includes radiology services such as MRI, CT scans, X-ray, ultrasound with colour doppler, mammography, Dexa scan, and interventional radiology; clinical laboratory services including haematology, microbiology, immunology, pathology, and biochemistry; and nuclear medicine services such as PET-CT, SPECT, and nuclear therapy. The company also operates a 24×7 teleradiology unit from Vijayawada and a processing laboratory at the same location. Service Model The business operates through four models: public-private partnership (PPP) with government hospitals and teaching institutions, private-private partnerships with hospitals, strategic partnerships with PSUs, and standalone private diagnostic centres. As of August 04, 2026, the company operated 16 diagnostic centres across seven states. As of March 31, 2026, the company had 161permanent employees. Competitive Strengths:

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: #: Issue Objects 1: Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres 2: General corporate purposes and unidentified inorganic acquisition : Total

All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application. No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever Please read all Tearms and conditions , and agree to use the App